Latest news and press releases about InflaRx N.V. (IFRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases.
Price
| Price | $2.04 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | DE |
Valuation Ratios
| Price / Book | 1.38 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -58.00% |
| Return on Invested Capital | -24.89% |
| Return on Assets | -23.46% |
| Gross Margin | 48201.61% |
| Operating Margin | 362271.47% |
| Net Margin | 387532.08% |
Related companies: ARTV · ATYR · CNTB · CNTX · IMA · KLRS · MGX
Explore sector: Healthcare · Biotechnology
More sections of IFRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks